Predictive Value of Protein Kinase C Delta as a Diagnostic Biomarker for Hepatocellular Carcinoma in Hepatitis C Virus-Related Cirrhosis
Abstract
Background/Aim: Hepatocellular carcinoma (HCC) is considered the 6th prevalent tumour and 3rd leading cause of cancer-associated mortality worldwide. Protein kinase C delta (PKCδ), released by liver cancer cells, has an effect in cell-proliferation and cancer formation, recommending PKCδ can serve as a good biomarker in HCC detection. The aim of this research was the assessment of predictive value of PKCδ as a diagnostic biomarker for HCC in hepatitis C virus (HCV)-related cirrhosis.
Methods: The study involved 180 participants, who were separated into three groups, the first control group included 45 healthy volunteers, the second cirrhotic without HCC group (non-HCC group) included 45 cirrhotic patients due to HCV and the third cirrhotic with HCC group (HCC group) included 90 cases with HCC on top of HCV-related cirrhosis. All participants were subjected to clinical examination, taking of history, radiological evaluation and routine laboratory investigations involving alpha-fetoprotein (AFP) assessment. PKCδ was assessed for all participants using Enzyme-Linked Immunosorbent Assay.
Results: AFP and PKCδ concentrations were greater in HCC than in non-HCC and controls. PKCδ ≥ 30.75 ng/mL showed excellent diagnostic performance for detecting HCC in HCV-related cirrhosis (AUC = 0.977, sensitivity 95.6 %, specificity 86.7 %, accuracy 92.6 %). Multivariate analysis identified PKCδ ≥ 30.75 ng/mL, AFP ≥ 9.4 ng/mL and current smoking as independent predictors of HCC.
Conclusion: PKCδ has a significant diagnostic ability for hepatocellular carcinoma (HCC), with good specificity and sensitivity in HCC prediction in patients with HCV-related liver cirrhosis.
References
Lee MH. Public health strategies for hepatocellular carcinoma: from risk factors to prevention and control. J Liver Cancer. 2025;25(2):204-16. doi: 10.17998/jlc.2025.07.25.
Hwang SY, Danpanichkul P, Agopian V, Mehta N, Parikh ND, Abou-Alfa GK, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol. 2025;31(Suppl):S228-S254. doi: 10.3350/cmh.2024.0824.
Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: a review of epidemiology and control measures. World J Gastrointest Oncol. 2021;13(12):1919-38. doi: 10.4251/wjgo.v13.i12.1919.
Ali AA, Gamal SE, Anwar R, Elzahaf E, Eskandere D. Assessment of clinico epidemiological profile of hepatocellular carcinoma in the last two decades. Egyptian J Intern Med. 2023;35(1):18.
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi: 10.1038/s41572-020-00240-3.
Ibrahim M, El Raey F, Fathy N, El Bakrey K. Transthyretin as a novel biomarker for diagnosis of hepatocellular carcinoma in cirrhotic patients. Int J Med Arts. 2020;2(2):412-19. doi: 10.21608/ijma.2020.23373.1094.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025 Feb;82(2):315-374. doi: 10.1016/j.jhep.2024.08.028.
Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922-65. doi: 10.1097/HEP.0000000000000466.
Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS. Biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2495-503. doi: 10.1158/1055-9965.EPI-20-0005.
Zou W, Cui J, Ren Z, Leng Y. NRAGE is a potential diagnostic biomarker of hepatocellular carcinoma. Medicine (Baltimore). 2018;97(48):e13411. doi: 10.1097/MD.0000000000013411.
Lu HC, Chou FP, Yeh KT, Chang YS, Hsu NC, Chang JG. Expression of protein kinase C family in human hepatocellular carcinoma. Pathol Oncol Res. 2010;16(3):385-91. doi: 10.1007/s12253-009-9228-z.
Rehman A, Shabbir M, Badshah Y, Khan K, Trembley JH, Ashraf NM, et al. Elucidating the role of missense SNP of protein kinase C epsilon in HCV induced hepatocellular carcinoma. BMC Cancer. 2023;23(1):147. doi: 10.1186/s12885-023-10618-7.
Ueda K, Oikawa T, Yamada K, Tsubota A, Saeki C, Katagiri K, et al. Serum PKCδ is a useful biomarker to distinguish hepatocellular carcinoma from other gastrointestinal cancers. Biochem Biophys Res Commun. 2025 Mar 5;751:151431. doi: 10.1016/j.bbrc.2025.151431.
Yamada K, Oikawa T, Kizawa R, Motohashi S, Yoshida S, Kumamoto T, et al. Unconventional secretion of PKCδ exerts tumorigenic function via stimulation of ERK1/2 signaling in liver cancer. Cancer Res. 2021;81(2):414-25. doi: 10.1158/0008-5472.CAN-20-2009.
Yamada K, Kizawa R, Yoshida A, Koizumi R, Motohashi S, Shimoyama Y, et al. Extracellular PKCδ signals to epidermal growth factor receptor for tumor proliferation in liver cancer cells. Cancer Sci. 2022;113(7):2378-85. doi: 10.1111/cas.15386.
Oikawa T, Yamada K, Tsubota A, Saeki C, Tago N, Nakagawa C, et al. Protein kinase C delta is a novel biomarker for hepatocellular carcinoma. Gastro Hep Adv. 2022;2(1):83-95. doi: 10.1016/j.gastha.2022.07.020.
Ammoury R, Tahtouh R, Mahfouz N, Doumit R, Khalil C, Hilal G. Relationship between protein kinase C isoforms, telomerase and alpha fetoprotein through PI3K/AKT/mTOR pathway in hepatocellular carcinoma. MedPharmRes. 2021;5(4):12-26.
Nakagawa C, Oikawa T, Yamada K, Tsubota A, Saeki C, Katagiri K, et al. Protein kinase C delta enhances the diagnostic performance of hepatocellular carcinoma. Biomarkers. 2024;29(2):55-67. doi: 10.1080/1354750X.2024.2312990.
Pugh RN, Murray Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-49. doi: 10.1002/bjs.1800600817.
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681-93. doi: 10.1016/j.jhep.2021.11.018.
Kamarajah SK, Frankel TL, Sonnenday C, Cho CS, Nathan H. Critical evaluation of the American Joint Committee on Cancer (AJCC) 8th edition staging system for patients with hepatocellular carcinoma: a SEER analysis. J Surg Oncol. 2018;117(4):644-50. doi: 10.1002/jso.24908.
Hui RW, Mak LY, Cheung TT, Lee VH, Seto WK, Yuen MF. Clinical practice guidelines and real life practice on hepatocellular carcinoma: the Hong Kong perspective. Clin Mol Hepatol. 2023;29(2):217-29. doi: 10.3350/cmh.2022.0399.
Calderon-Martinez E, Landazuri-Navas S, Vilchez E, Cantu-Hernandez R, Mosquera-Moscoso J, Encalada S, et al. Prognostic scores and survival rates by etiology of hepatocellular carcinoma: a review. J Clin Med Res. 2023;15(4):200-7. doi: 10.14740/jocmr4902.
Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging score (JIS score). J Gastroenterol. 2003;38(3):207-15. doi: 10.1007/s005350300038.
Arias IM, Alter HJ, Boyer JL, Eds. Epidemiology of hepatocellular carcinoma. In: The Liver: Biology and Pathobiology. Hoboken, US: Wiley 2020. pp. 758-72.
Jain D, Chaudhary P, Varshney N, Bin Razzak KS, Verma D, Khan Zahra TR, et al. Tobacco smoking and liver cancer risk: potential avenues for carcinogenesis. J Oncol. 2021;2021:5905357. doi: 10.1155/2021/5905357.
Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, et al. Risk factors, pathogenesis, and strategies for hepatocellular carcinoma prevention: emphasis on secondary prevention and its translational challenges. J Clin Med. 2020;9(12):3817. doi: 10.3390/jcm9123817.
Shadi Y, Heshmati B, Poorolajal J. Interaction between hepatitis B, hepatitis C and smoking in the development of hepatocellular carcinoma: a systematic review and meta analysis. J Public Health (Oxf). 2024;46(1):51-60. doi: 10.1093/pubmed/fdad214.
Aasarey R, Yadav K, Kashyap BK, Prabha S, Kumar P, Kumar A, et al. Role of immunological cells in hepatocellular carcinoma disease and associated pathways. ACS Pharmacol Transl Sci. 2023;6(12):1801-16. doi: 10.1021/acsptsci.3c00216.
Seyhan D, Allaire M, Fu Y, Conti F, Wang XW, Gao B, et al. Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy. Cell Mol Immunol. 2025;22(10):1132-58. doi: 10.1038/s41423-025-01308-4.
Toqueer U, Manan A, Riyaz A, Zaman A, Shafi R, Anis R, et al. Correlation of liver enzymes and blood parameters with histopathological severity in benign and malignant liver lesions. Cureus. 2025;17(9):e92954. doi: 10.7759/cureus.92954.
Jeng LB, Chan WL, Teng CF. Prognostic significance of serum albumin level and albumin based mono and combination biomarkers in patients with hepatocellular carcinoma. Cancers (Basel). 2023;15(4):1005. doi: 10.3390/cancers15041005.
Bihari C, Rastogi A, Shasthry SM, Bajpai M, Bhadoria AS, Rajesh S, et al. Platelets contribute to growth and metastasis in hepatocellular carcinoma. APMIS. 2016;124(9):776-86. doi: 10.1111/apm.12574.
Zanetto A, Senzolo M, Campello E, Bulato C, Gavasso S, Shalaby S, et al. Influence of hepatocellular carcinoma on platelet aggregation in cirrhosis. Cancers (Basel). 2021;13(5):1150. doi: 10.3390/cancers13051150.
Gouda AM, Abd Elaziz MA, Mousa MA, Saad HM, Helaly NA. Evaluation of platelet indices in Egyptian cirrhotic patients. Afr J Gastroenterol Hepatol. 2024;7(1):163-84. doi: 10.21608/ajgh.2024.282311.1052.
Sharma P. Value of liver function tests in cirrhosis. J Clin Exp Hepatol. 2022;12(3):948-64. doi: 10.1016/j.jceh.2021.11.004.
Sheta T, Selim M, Sabry M, Saed A. Serum thioredoxin as a diagnostic marker for hepatocellular carcinoma in cirrhotic hepatitis C patients. Med J Viral Hepat. 2021;5(2):9-15. doi: 10.21608/mjvh.2021.158271.
Lee WC. Value of alpha fetoprotein in hepatocellular carcinoma. Transl Gastroenterol Hepatol. 2021;6:52. doi: 10.21037/tgh.2019.12.19.
Huang D, Zhang J, Xu J, Niu Q, Zhou D. Utility of alpha fetoprotein and ultrasound in the diagnosis and prognosis of patients with hepatocellular liver cancer. J Multidiscip Healthc. 2024;17:1819-26. doi: 10.2147/JMDH.S449276.
Che Noh I, Avoi R, Abdullah Nurul A, Ahmad I, Abu Bakar R. Analysis of serum and gene expression profile of cytokines (IL 6, TNF α and TGF β1) in chronic hepatitis C virus infection. PeerJ. 2022;10:e13330. doi: 10.7717/peerj.13330.
Qin S, Wang J, Yuan H, He J, Luan S, Deng Y. Liver function indicators and risk of hepatocellular carcinoma: a bidirectional mendelian randomization study. Front Genet. 2024;14:1260352. doi: 10.3389/fgene.2023.1260352.
Hanif M, Mobeen N, Huda N, Nagra MA, Hussain HA, Ahmed U, et al. Correlation of elevated serum alpha feto protein level with mean tumor size in hepatocellular carcinoma. Ann Punjab Med Coll. 2020;14(3). doi: 10.29054/APMC/2020.987.
Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, et al. Update on the applications and limitations of alpha fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 2022;28(2):216-29. doi: 10.3748/wjg.v28.i2.216.
Hamayun A, Anees S, Gardezi A, Khan Niazi N, Tirmizi SH, Rafique I, et al. Evaluation of co relation between BCLC stage of HCC and alpha fetoprotein levels. Pakistan J Med Health Sci. 2022;16(08):104. doi: 10.53350/PJMHS22168104.
Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870. doi: 10.1038/s41598-017-12834-1.
Feng D, Wang M, Hu J, Li S, Zhao S, Li H, et al. Prognostic value of the albumin bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. Ann Transl Med. 2020;8(8):553. doi: 10.21037/atm.2020.02.116.
da Fonsecaa LG, de Melo MAZ, da Silveira THM, Yamamoto VJ, Hashizume PHS, Sabbaga J. Prognostic role of albumin bilirubin (ALBI) score and Child Pugh classification in patients with advanced hepatocellular carcinoma under systemic treatment. Ecancermedicalscience. 2024;18:1748. doi: 10.3332/ecancer.2024.1748.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).